106 results about "Mediator" patented technology

The presence of oxygen or red blood cells in a sample applied to an electrochemical test strip that makes use of a reduced mediator is corrected for by an additive correction factor that is determined as a function of the temperature of the sample and a measurement that reflects the oxygen carrying capacity of the sample. The measured oxygen carrying capacity can also be used to determine hematocrit and to distinguish between blood samples and control solutions applied to a test strip.

Compounds of Formula I are useful as mediators of protein kinases and have activity as cell proliferation inhibitors:where X, R1–R7 and R9 are as defined herein.

The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3 / αGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed

The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

The invention discloses a Fc fusion protein of long-acting recombinant human growth hormone. The Fc fusion protein (hGH-L-vFc fusion protein) disclosed herein contains human growth hormone, flexible peptide linker of about 2-20 amino acids, and human IgG Fc mutant. The Fc mutant is not lytic and has tiny side effect of adverse Fc-mediator. The invention further discloses a method for preparing or generating the fusion protein with high expression level. The hGH-L-vFc fusion protein disclosed herein has prolonged serum half-life period and increased biological activity, so as to improve the pharmacokinetics and drug efficacy, and needs few times of injection required in treatment.

The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and (ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.

The invention relates to an electrochemical immunosensor, and in particular relates to a sandwich type electrochemical immunosensor which is constructed by taking Au-hybridized mesoporous carbon CMK-3(Au@CMK-3) and two electronic mediators, namely neutral red and thionine, as second antibody markers, a preparation method of the sandwich type electrochemical immunosensor, and application of the electrochemical immunosensor, which is prepared by the method, to simultaneous detection on markers of a cervical cancer. The electrochemical immunosensor can be used for simultaneously detecting two samples and overcoming the limitation of a single index, plays an important role in further improvement of the early confirming rate of the cervical cancer, and can be popularized to the field of simultaneous detection on tumor markers of other cancers.

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The invention discloses a trypsin-chymotrypsin electrochemical synchronous detection method based on enzyme digestion and belongs to the technical field of electrochemical sensing. Through gold-mercapto bond action, a DNA-polypeptide compound is fixed to the surface of a gold electrode, and through DNA hybridization reaction, a DNA-gold nanoparticle-electronic mediator nanometer signal probe is captured. When target protease exists, an arginine carboxyl site of one of polypeptides is cut by trypsin and a tyrosine carboxyl site of the other one of the polypeptides is cut by chymotrypsin so that the corresponding nanometer signal probes connected to the polypeptides are separated from the surface of the electrode and thus peak current of the corresponding electronic mediator is reduced. Therefore, the trypsin-chymotrypsin electrochemical synchronous detection method can realize synchronous detection of sensitivity and selectivity of trypsin and chymotrypsin.

Integrin-linked kinase (ILK) and Akt / protein kinase B (PKB) are important mediators of signaling in cardiomyocytes and can both prevent damage and promote healing associated with ischemic injury to the heart. Thus, the present invention provides for methods of screening for agents that increase the expression of ILK and / or Akt / PKB. Methods of treatment based on such agents are also provided.

The invention relates to a mediator probe comprising a probe region and a mediator region. Furthermore, the invention relates to a system comprising a mediator probe and a detection molecule, use of that system and a method for detection of at least one target molecule.

The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.

Compositions and methods for electrochemical detection of an analyte comprising a transition metal compound wherein M is a metallic element that can form a coordinate bond to nitrogen; R and R′ are coordinated to M at their nitrogen atoms; L is a linking ligand; Z is chlorine or bromine; m can be from 1 to 6 and X is an anion, or combination of anions, that balances the charge m. Also provided are electrochemical tags and methods of detection.

The invention relates to a method of and apparatus for determining concentration of an analyte, such as glucose, in a fluid sample, such as body fluid or control solution, using a mediated redox reaction. In particular, the method relates to mitigation of the effects of haematocrit on the response of sensor device used in such a method or apparatus. The invention describes a method of determining concentration of an analyte in a fluid sample deposited on a sensor device having a working electrode and a counter electrode, in which the electrodes are provided with an enzyme and a mediator for carrying out a mediated redox reaction, the method comprising: applying a first oxidising potential between the working and counter electrodes during a first time period; applying a second reducing potential between the working and counter electrodes during a second time period; determining a reaction parameter, the reaction parameter being indicative of the concentration of reduced mediator at the counter electrode after commencement of the second time period; using the reaction parameter to determine the concentration of analyte.

The present invention relates to the mechanism of ARF-mediated cell growth suppression. ARF-BP1 is identified as a novel ubiquitin ligase, and a major component of ARF-containing nuclear complexes in human cells. The present invention discloses a novel mechanism of ARF-mediated p53 activation and that ARF-BP1 is a critical mediator of both p53-independent and p53-dependent tumor suppression functions of ARF. Inactivation of ARF-BP1 in normal cells stabilizes p53 and induces p53-dependent apoptosis. Inactivation of ARF-BP1, but not Mdm2, in p53-wildtype cells promotes cell growth inhibition in a manner reminiscent of ARF induction. ARF-BP1 directly binds and ubiquitinates p53 and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization in Mdm2-null cells. ARF-BP1 is advantageous over Mdm2 as a target for suppressing tumor cell growth regardless of p53 status.

The present invention relates to methods for dynamically detecting the interactions between various materials including bioactive molecules and for detecting target molecules. More specifically, the present invention relates to a method for dynamically detecting bait-prey interactions and a method for easily detecting target molecules which blocks or activates the interactions, the method comprising: allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, and analyzing whether a nano-assembly matrix is formed by the interaction between the bait and the prey in vitro or in vivo; or allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, inducing the formation of a nano-assembly matrix by a mediator (regulator) material in vitro or in vivo, and then analyzing whether the prey and the bait co-localizes on the nano-assembly matrix.

Methods for identifying modulators of fatty acid transport and / or uptake, comprising contacting, under conditions favorable for fatty acid uptake, a putative modulator, e.g., an inhibitor with a system comprising genetic material encoding a fatty acid transport mediator (“TTM”), particularly FAA1, FAA2, FAA3, FAA4, FAT1, fadL, fadD, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, or fatty acid transport mediator proteins (“TTMps”), e.g., Faa1p, Faa2p, Faa3p, Faa4p, Fat1p, FadL, fatty acyl CoA synthetase, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, and determining the effect of the putative modulator. The test system may be a cell such as Saccharomyces cerevisiae, E. coli, H. sapiens, etc. or an in vitro system.

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g.,to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The present invention provides a calorimetric method that can perform a simple and reliable analysis in a short time. The method includes transferring an electron from an analyte to a coloring reagent that produces color by reduction via a mediator by using an oxidoreductase; and performing qualitative or quantitative analysis of the analyte by measuring color produced in the coloring reagent. The enzyme reaction of this method is a single stage reaction, and the color production reaction occurs via the mediator. Therefore, the measurement can be performed in a short time. Since this reaction requires neither hydrogen peroxide nor oxygen, the measured values are highly reliable.

The present invention discloses a method for evaluating the allergen sensitivity of an individual and / or the clinical efficacy of an allergen immunotherapy comprising the steps: providing at least two samples selected from the group consisting of blood or fractions thereof, connective tissue, nasal, bronchial, skin or gut biopsy material from an individual subjected or intended to be subjected to an immunotherapy with at least one pure allergen or derivative thereof, wherein the samples contain cells capable of releasing mediators in response to said allergen, contacting said sample with said allergen or derivative thereof, and determining the amounts of mediators released from said sample and evaluating the allergen sensitivity of the individual prior to therapy and / or the clinical efficacy of the immunotherapy by comparing said amounts.

The present invention concerns a mediator probe for the detection of at least one target molecule comprising at least two oligonucleotides. A first oligonucleotide of the mediator probe according to the invention comprises a probe region and a mediator binding region, wherein the probe region has an affinity to a target molecule and / or template molecule, and the mediator binding region has an affinity to at least one mediator. At least one further oligonucleotide of the mediator probe is a mediator which is bound to the first oligonucleotide of the mediator probe via the mediator binding region and has an affinity for at least one detection molecule, wherein the mediator triggers a detectable signal by interaction with the detection molecule after release from the first oligonucleotide of the mediator probe. Furthermore, the present invention concerns a system comprising at least one mediator probe according to the invention and at least one detection molecule, as well as a method for the detection of at least one target molecule.

The present invention relates to a method for identifying allergenic proteins and peptides. More specifically, the present invention provides a method for identifying allergenic milk proteins and / or peptides comprising the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating mammal, preferably a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to mammalian milk,preferably cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide at least one mediator.

The present invention relates to the mechanism of ARF-mediated cell growth suppression. ARF-BP1 is identified as a novel ubiquitin ligase, and a major component of ARF-containing nuclear complexes in human cells. The present invention discloses a novel mechanism of ARF-mediated p53 activation and that ARF-BP1 is a critical mediator of both p53-independent and p53-dependent tumor suppression functions of ARF. Inactivation of ARF-BP1 in normal cells stabilizes p53 and induces p53-dependent apoptosis. Inactivation of ARF-BP1, but not Mdm2, in p53-wildtype cells promotes cell growth inhibition in a manner reminiscent of ARF induction. ARF-BP1 directly binds and ubiquitinates p53 and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization in Mdm2-null cells. ARF-BP1 is advantageous over Mdm2 as a target for suppressing tumor cell growth regardless of p53 status.

The invention discloses a Bim (Bcl-2 interacting mediator of cell death) gene deletion fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe and a detection reagent kit, and belongs to the field of molecular biological detection. The Bim gene deletion fluorescent quantitative PCR detection primer and the probe comprise forward primers 5'-CAACAAACCCATCAGAACAGACAC-3', reverse primers 5'-ACAGCCTCTATGGAGAACAGTGATT-3 and fluorescent probes 5'-FAM-CAGACACTGGAACAAA-MGB-3'. The detection reagent kit comprises the Bim gene deletion fluorescent quantitative PCR detection primer, the probe, premixed liquid of PCR liquid and positive control samples A. The Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit have the advantages that Bim gene deletion mutation can be detected by the aid of the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit, and the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit are simple, convenient and feasible and are high in accuracy and sensitivity and particularly suitable for detecting clinical samples; Bim deletion mutation can be detected, and accordingly the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit can bring convenience for guiding individual treatment on bodies.

The invention relates to a duplex RT-PCR method for synchronous detection of WDV (wheat dwarf virus) and WYSV (wheat yellow striate virus). Specific primers shown as SEQ ID No .1\2 for the WDV and specific primers shown as SEQ ID No .3\4 for the WYSV are adopted, RNA of a sample containing the two viruses is taken as a template, SEQ ID No .2\4 are taken as primers for reverse transcription, viruscDNA is obtained, the four primers are added to one PCR reaction system, 773bp and 332bp products are obtained respectively, and various parameters in the reaction process are optimized simultaneously. The duplex RT-PCR method established on the basis of the primers and used for the WDV and the WYSV is high in specificity and sensitivity, the two viruses in mediators can be detected and identifiedin one system synchronously, rapidly and accurately, good monitoring and early warning can be realized, and diseases are controlled before pandemic of virus diseases finally.

The present invention discloses novel therapeutic complex molecules, and in particular, peptidic or peptidomimetic molecules, comprising a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine secretion from mast cells and protein kinase activation, wherein the first part is connected to the second part via a linker or a direct bond that creates a conformational constraint by forming a bend or turn.

The present invention provides a microbial cell capable of producing at least one terminal alkene from at least one short chain fatty acid, wherein the cell is genetically modified to compriseat least a first genetic mutation that increases the expression relative to the wild type cell of an enzyme (E1) selected from the CYP152 peroxygenase family, andat least a second genetic mutation that increases the expression relative to the wild type cell of at least one NAD(P)+ oxidoreductase (E2) and the corresponding mediator protein,wherein the short chain fatty acid is a C4-C10 fatty acid.

The present invention belongs to the field of agricultural biology and particularly relates to fungal-derived laccase TvLac and a coding gene and an application thereof. The present invention provides the laccase TvLac derived from trametes versicolor. The laccase can effectively degrade mycotoxins of different structure types with an aid of a mediator and can be widely used in fields of mycotoxin detoxification of food and feeds.